[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100592557":3},{"organization":4,"outcomesModule":7,"designInfo":52,"detailedDescription":62,"studyPopulation":51,"armGroups":63,"interventions":74,"overallOfficials":51,"centralContacts":83,"locations":89,"responsibleParty":116,"collaborators":51,"id":120,"slug":51,"hasResults":121,"nctId":122,"briefTitle":123,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":121,"sex":126,"minAge":127,"maxAge":51,"enrollmentInfo":128,"targetDuration":51,"studyType":131,"phases":132,"briefSummary":134,"conditions":135,"keywords":51,"overallStatus":91,"whyStopped":51,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":146},{"fullName":5,"class":6},"Huashan Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":51},[9],{"measure":10,"description":11,"timeFrame":12},"Proportion of Participants Achieving Excellent Functional Outcome (mRS 0-1) at 90±7 Days","The primary outcome is the proportion of participants achieving excellent functional outcome (free of disability, defined as a modified Rankin Scale \\[mRS\\] score of 0-1) at 90±7 days.","at 90±7 days",[14,18,21,24,28,32,35,38,41,45,48],{"measure":15,"description":16,"timeFrame":17},"Infarct Growth Volume at 3-5 Days Compared to Baseline Core","The secondary radiological efficacy outcome is infarct growth, defined as the difference in volume between the infarct volume measured by diffusion-weighted imaging (DWI) or non-contrast head CT at 3-5 days and the baseline core infarct volume.","at 3-5 days",{"measure":19,"description":20,"timeFrame":12},"Proportion of Participants Achieving Good Functional Outcome (mRS 0-2) at 90±7 Days","The secondary clinical efficacy outcome is the proportion of participants achieving good functional outcome (functional independence, defined as a modified Rankin Scale \\[mRS\\] score of 0-2) at 90±7 days.",{"measure":22,"description":23,"timeFrame":12},"Distribution of Modified Rankin Scale Scores at 90±7 Days","The secondary clinical efficacy outcome is the distribution of modified Rankin Scale (mRS) scores from 0 (no symptoms) to 6 (death) at 90±7 days post-treatment.",{"measure":25,"description":26,"timeFrame":27},"Proportion of Participants with Significant Neurological Improvement within 24-48 Hours","The secondary clinical efficacy outcome is the proportion of participants achieving significant neurological improvement within 24-48 hours, defined as a reduction in National Institutes of Health Stroke Scale (NIHSS) score by more than 8 points or an NIHSS score of 0-1.","within 24-48 hours",{"measure":29,"description":30,"timeFrame":31},"Change in NIHSS Score at 24-48 Hours","The secondary clinical efficacy outcome is the change in National Institutes of Health Stroke Scale (NIHSS) score as a continuous variable at 24-48 hours post-treatment.","at 24-48 hours",{"measure":33,"description":34,"timeFrame":27},"Incidence of Symptomatic Intracranial Hemorrhage within 24-48 Hours","The secondary radiological safety outcome is the incidence of symptomatic intracranial hemorrhage within 24-48 hours post-treatment, defined according to the European Cooperative Acute Stroke Study III (ECASS III) criteria.",{"measure":36,"description":37,"timeFrame":31},"Incidence of Any Intracranial Hemorrhage within 24-48 Hours Post Treatment","The secondary radiological safety outcome is the incidence of any intracranial hemorrhage within 24-48 hours post-treatment, as determined by computed tomography \\[CT\\].",{"measure":39,"description":40,"timeFrame":31},"Incidence of PH2 within 24-48 Hours Post Treatment","The secondary radiological safety outcome is the incidence of type 2 parenchymal hematoma (PH2) within 24-48 hours post-treatment, as determined by computed tomography \\[CT\\].",{"measure":42,"description":43,"timeFrame":44},"Incidence of All-Cause Mortality within 90 Days","The secondary clinical safety outcome is the incidence of all-cause mortality within 90 days post-treatment.","within 90 days",{"measure":46,"description":47,"timeFrame":12},"Proportion of Participants with Poor Functional Outcome (mRS 5-6) at 90±7 Days","The secondary clinical safety outcome is the proportion of participants with poor functional outcome (severe disability or death, defined as modified Rankin Scale \\[mRS\\] score of 5-6) at 90±7 days post-treatment.",{"measure":49,"description":50,"timeFrame":44},"Incidence of Systemic Bleeding within 90 Days","The secondary clinical safety outcome is the incidence of systemic bleeding within 90 days post-treatment, defined according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) criteria.",null,{"allocation":53,"interventionModel":54,"interventionModelDescription":55,"primaryPurpose":56,"observationalModel":51,"timePerspective":51,"maskingInfo":57},"RANDOMIZED","PARALLEL","Multicenter, open-label, blinded-endpoint, randomized, controlled, phase 3 trial","TREATMENT",{"masking":58,"maskingDescription":59,"whoMasked":60},"SINGLE","Blinded-endpoint",[61],"OUTCOMES_ASSESSOR","CHinese ischEmic Stroke beyond 4.5 Hours with TeNecteplase Under optimized Non-Contrast CT selection (CHESTNUT) is a multicenter, open-label, blinded-endpoint, randomized, controlled, phase 3 study. Patients with acute strokes who are unable to undergo endovascular thrombectomy and exhibit no substantial infarction lesion on non-contrast computed tomography (less than 50 mL according to the automated NCCT post-processing model and no visible hypodensity in more than 1\u002F3 of the middle cerebral artery \\[MCA\\] territory) are randomly assigned in a 1:1 ratio to receive either 0.25 mg\u002Fkg TNK or standard medical treatment. The efficacy and safety of 0.25 mg\u002Fkg TNK are assessed through clinical prognosis at 90 days.",[64,69],{"label":65,"type":66,"description":51,"interventionNames":67},"0.25mg\u002Fkg TNK group","EXPERIMENTAL",[68],"Drug: 0.25mg\u002Fkg TNK",{"label":70,"type":71,"description":51,"interventionNames":72},"Standard medical treatment","PLACEBO_COMPARATOR",[73],"Drug: Standard medical treatment",[75,80],{"type":76,"name":77,"description":78,"armGroupLabels":79,"otherNames":51},"DRUG","0.25mg\u002Fkg TNK","Patients in the tenecteplase group were administered a 0.25mg\u002Fkg dose as a bolus over 5-10 seconds, followed by a 2 mL saline flush.",[65],{"type":76,"name":70,"description":81,"armGroupLabels":82,"otherNames":51},"Patients in the standard medical treatment group will receive the standard treatment selected by local doctors, including antithrombotic agents, lipid-lowering agents, antihypertensive drugs, and hypoglycemic agents. Patients would be ineligible if bridging endovascular treatment is planned at the time of randomization.",[70],[84],{"name":85,"role":86,"phone":87,"phoneExt":51,"email":88},"Xin Cheng, MD, PhD","CONTACT","+86 021-52887145","chengxin@fudan.edu.cn",[90,108],{"facility":5,"status":91,"city":92,"state":93,"zip":94,"country":95,"countryCode":96,"cosmosGeoPoint":97,"geoPoint":102,"contacts":103},"RECRUITING","Shanghai","Shanghai Municipality","200040","China","CN",{"type":98,"coordinates":99},"Point",[100,101],121.45806,31.22222,{"lat":101,"lon":100},[104],{"name":105,"role":86,"phone":106,"phoneExt":51,"email":107},"Wei Huang","52888046","hskyc@fudan.edu.cn",{"facility":109,"status":110,"city":92,"state":51,"zip":51,"country":95,"countryCode":96,"cosmosGeoPoint":111,"geoPoint":113,"contacts":114},"Huashan Hospital, Fudan University","NOT_YET_RECRUITING",{"type":98,"coordinates":112},[100,101],{"lat":101,"lon":100},[115],{"name":85,"role":86,"phone":87,"phoneExt":51,"email":88},{"type":117,"investigatorFullName":118,"investigatorTitle":119,"investigatorAffiliation":5,"oldNameTitle":51,"oldOrganization":51},"PRINCIPAL_INVESTIGATOR","Xin Cheng","Professor and Vice Chair, Department of Neurology, Huashan Hospital, Fudan University","100592557",false,"NCT06994975","CHinese ischEmic Stroke Beyond 4.5 Hours With TeNecteplase Under Optimized Non-Contrast CT Selection","CHESTNUT","Inclusion Criteria:\n\n1. Suspected acute ischemic stroke of anterior cerebral circulation.\n2. Last known well time \\>4.5 hours.\n3. Age ≥18 years old.\n4. Baseline NIHSS (National Institutes of Health Stroke Scale) score \\>5.\n5. Premorbid modified Rankin Scale (mRS) ≤1.\n6. Imaging criteria: Automated infarct segmentation by NCCT post-processing model indicates infarct core volume \\\u003C50 mL with no visible hypodensity in \\>1\u002F3 of the MCA territory.\n7. Informed consent signed by the patient or the patient's legally authorized representative.\n\nExclusion Criteria:\n\n1. Obvious hypodensity on NCCT deemed related with the current stroke event, with no expected benefit from thrombolysis as assessed by the investigators\n2. Endovascular thrombectomy (EVT) planned at the time of randomization\n3. Allergy to the test drug and its ingredients\n4. Rapidly improving symptoms at the discretion of the investigator\n5. Any sign of an acute intracranial hemorrhage or subarachnoid hemorrhage identified on baseline NCCT\n6. History of any intracranial hemorrhage\n7. History of ischemic stroke or major head trauma within the last 3 months\n8. History of intracranial\u002Fintraspinal surgery during the last 3 months\n9. Gastrointestinal malignancy or gastrointestinal bleeding within 21 days\n10. Known bleeding diatheses; platelets count \\\u003C 100000\u002Fmm3, international normalized ratio \\> 1.7, prothrombin time \\> 15 s, or activated partial thromboplastin clotting time \\> 40 s\n11. Treatment with a full dosage of low-molecular weighted heparin in the last 24 hours\n12. Treatment with direct thrombin inhibitors or direct factor Xa inhibitors within the previous 48 hours unless the laboratory test of coagulation function is normal\n13. Initial systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥100 mmHg\n14. Initial glucose levels \\\u003C2.8 or 22.22 mmol\u002FL\n15. Known or suspected aortic arch dissection\n\nIn addition to:\n\n1. Clinical presentation or imaging profile consistent with Moyamoya disease\u002Fsyndrome.\n2. Pregnancy or breastfeeding.\n3. Recent participation in another investigational drug or device study or registry in the past 30 days before enrollment.\n4. Any terminal illness such that the patient would not be expected to survive more than three months.\n5. Other conditions in which investigators believe that participating in this study may be harmful to the patient.","ALL","18 Years",{"count":129,"type":130},890,"ESTIMATED","INTERVENTIONAL",[133],"PHASE3","The CHESTNUT trial is a multicenter, open-label, blinded-endpoint, randomized, controlled, phase 3 trial. The primary objective of this study is to explore the efficacy and safety of the dose of 0.25 mg\u002Fkg tenecteplase (TNK) in Chinese acute ischemic stroke (AIS) patients without substantial infarction on non-contrast computed tomography (NCCT) in an extended time window.",[136],"Acute Ischemic Stroke","2025-12-22",{"date":139,"type":140},"2025-12-30","ACTUAL",{"date":142,"type":140},"2025-11-03",{"date":144,"type":130},"2028-06",{"name":5,"class":6},2]